{"id":"W4387809927","doi":"10.1016/j.annonc.2023.09.3100","title":"354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Seagen; Relay Therapeutics; Incyte; Daiichi-Sankyo; Pfizer; Genentech; Mersana Therapeutics; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adjuvant therapy; Oncology; Tamoxifen; Fulvestrant; Breast cancer; Adjuvant; Aromatase inhibitor; Hazard ratio; Cancer; Trastuzumab; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006802552,0.0003573945,0.001807418,0.0003075348,0.000043722,0.00001086341,0.0003048584,0.0000783125,0.0000694326],"category_scores_gemma":[0.00004465497,0.0002176266,0.0000398638,0.0006100984,0.0004741385,0.0003193898,0.00007534281,0.0002876374,2.609272e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005967927,"about_ca_system_score_gemma":0.0007165092,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00721411,"about_ca_topic_score_gemma":0.004055997,"domain_scores_codex":[0.9972595,0.0005017153,0.0008369609,0.0005382043,0.0004312167,0.0004324116],"domain_scores_gemma":[0.9973378,0.0003155246,0.0009331796,0.000477253,0.0007681915,0.0001680744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.549794,0.00840446,0.07871648,0.00004571563,0.000739402,0.00007690472,0.004965319,0.00002702735,0.000515437,0.000007427303,0.00001195798,0.3566959],"study_design_scores_gemma":[0.3848279,0.08824291,0.5238347,0.0003300218,0.00008091751,0.00001299993,0.0008725025,0.00002304956,0.001480616,0.00005630392,0.00006995223,0.000168143],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994817,0.0003576849,0.00002693094,0.0004298599,0.00008675092,0.00363468,0.0006030863,0.00002806768,0.00001599226],"genre_scores_gemma":[0.9916474,0.007281641,0.0003103548,0.000188199,0.00003448563,0.0004184132,0.00003757466,0.00005563058,0.00002632474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4451182,"threshold_uncertainty_score":0.9993969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06015312760793879,"score_gpt":0.4174183995271137,"score_spread":0.3572652719191749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}